Open3.900 | Close3.805 |
Vol / Avg.278.900K / 500.584K | Mkt Cap235.000M |
Day Range3.800 - 3.990 | 52 Wk Range0.991 - 7.330 |
Inozyme Pharma Stock (NASDAQ: INZY) stock price, news, charts, stock research, profile.
Open3.900 | Close3.805 |
Vol / Avg.278.900K / 500.584K | Mkt Cap235.000M |
Day Range3.800 - 3.990 | 52 Wk Range0.991 - 7.330 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.320 | -0.290 | 0.0300 | ||||
REV | 0 |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.430 | -0.350 | 0.0800 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-11-08 | Needham | Joseph Stringer | Reiterates | BuyBuy | Maintains | - | 23.00 |
2023-09-27 | Needham | Joseph Stringer | Reiterates | BuyBuy | Maintains | - | 23.00 |
2023-09-08 | Wedbush | David Nierengarten | Maintains | OutperformOutperform | Announces | - | 15.00 |
2023-08-09 | Needham | Joseph Stringer | Reiterates | BuyBuy | Maintains | - | 23.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
INZY | Inozyme Pharma | -3.18% | 235M |
RENB | Renovaro Biosciences | -1.79% | 220.1M |
PGEN | Precigen | 0.85% | 293.7M |
IMRX | Immuneering | 0.98% | 241.5M |
FATE | Fate Therapeutics | -4.68% | 220.9M |
You can purchase shares of Inozyme Pharma (NASDAQ: INZY) through any online brokerage.
Other companies in Inozyme Pharma’s space includes: Renovaro Biosciences (NASDAQ:RENB), Precigen (NASDAQ:PGEN), Immuneering (NASDAQ:IMRX), Fate Therapeutics (NASDAQ:FATE) and Opthea (NASDAQ:OPT).
The latest price target for Inozyme Pharma (NASDAQ: INZY) was reported by Needham on Wednesday, November 8, 2023. The analyst firm set a price target for 23.00 expecting INZY to rise to within 12 months (a possible 504.47% upside). 13 analyst firms have reported ratings in the last year.
The stock price for Inozyme Pharma (NASDAQ: INZY) is $3.805 last updated December 8, 2023 at 9:00 PM UTC.
There is no dividend information for Inozyme Pharma.
Inozyme Pharma’s Q3 earnings are confirmed for Tuesday, November 7, 2023.
There is no upcoming split for Inozyme Pharma.
Inozyme Pharma is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.